FDA Guidance Advises on Developing GnRH Analogues for Advanced Prostate Cancer
July 29, 2022
In an effort to get more gonadotropin-releasing hormone (GnRH) analogues to market for advanced prostate cancer patients, the FDA has published final guidance that advises sponsors to conduct single-arm trials using T levels as pharmacodynamics/response biomarkers.